Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study.
- DOI
- 10.55563/clinexprheumatol/fkmsi2
- Published
- 2021 Jul-Aug
- Container
- Clinical and experimental rheumatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.55563/clinexprheumatol/fkmsi2,
title = {Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study.},
author = {Saraux A and Combe B and Fagnani F and Cukierman G and Bru I and Joubert JM and Schuller JC and Massol J and Flipo RM},
year = {2021},
journal = {Clinical and experimental rheumatology},
doi = {10.55563/clinexprheumatol/fkmsi2},
url = {https://doi.org/10.55563/clinexprheumatol/fkmsi2}
}RIS
TY - JOUR TI - Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study. AU - Saraux A AU - Combe B AU - Fagnani F AU - Cukierman G AU - Bru I AU - Joubert JM AU - Schuller JC AU - Massol J AU - Flipo RM PY - 2021 JO - Clinical and experimental rheumatology DO - 10.55563/clinexprheumatol/fkmsi2 UR - https://doi.org/10.55563/clinexprheumatol/fkmsi2 ER -
APA
A, S., B, C., F, F., G, C., I, B., JM, J., JC, S., J, M., & RM, F. (2021). Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study.. Clinical and experimental rheumatology. https://doi.org/10.55563/clinexprheumatol/fkmsi2
Source records
- pubmed · retrieved 2026-09-25T18:18:09.784Z